scholarly journals The lag time from symptoms onset of rheumatoid arthritis to initiation of Methotrexate: data from the Moroccan register of biotherapies

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
M Eddaoudi ◽  
S Rostom ◽  
I Hmamouchi ◽  
I El Binoune ◽  
B Amine ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Lag Time

Development and Evaluation of Floating Pulsatile Drug Delivery System Using Meloxicam

2017 ◽  
Vol 7 (04) ◽  
Author(s):  
ShirishaG. Suddala ◽  
S. K. Sahoo ◽  
M. R. Yamsani
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Delivery ◽  
Drug Release ◽  
Drug Delivery System ◽  
Delivery System ◽  
Lag Time ◽  
Oral Dosage ◽  
Lag Phase ◽  
Pulsatile Drug Delivery

Objective: The objective of this research work was to develop and evaluate the floating– pulsatile drug delivery system (FPDDS) of meloxicam intended for Chrono pharmacotherapy of rheumatoid arthritis. Methods: The system consisting of drug containing core, coated with hydrophilic erodible polymer, which is responsible for a lag phase for pulsatile release, top cover buoyant layer was prepared with HPMC K4M and sodium bicarbonate, provides buoyancy to increase retention of the oral dosage form in the stomach. Meloxicam is a COX-2 inhibitor used to treat joint diseases such as osteoarthritis and rheumatoid arthritis. For rheumatoid arthritis Chrono pharmacotherapy has been recommended to ensure that the highest blood levels of the drug coincide with peak pain and stiffness. Result and discussion: The prepared tablets were characterized and found to exhibit satisfactory physico-chemical characteristics. Hence, the main objective of present work is to formulate FPDDS of meloxicam in order to achieve drug release after pre-determined lag phase. Developed formulations were evaluated for in vitro drug release studies, water uptake and erosion studies, floating behaviour and in vivo radiology studies. Results showed that a certain lag time before drug release which was due to the erosion of the hydrophilic erodible polymer. The lag time clearly depends on the type and amount of hydrophilic polymer which was applied on the inner cores. Floating time and floating lag time was controlled by quantity and composition of buoyant layer. In vivo radiology studies point out the capability of the system of longer residence time of the tablets in the gastric region and releasing the drug after a programmed lag time. Conclusion: The optimized formulation of the developed system provided a lag phase while showing the gastroretension followed by pulsatile drug release that would be beneficial for chronotherapy of rheumatoid arthritis and osteoarthritis.

scholarly journals Lag time between disease onset and first visit to a tertiary rheumatology centre by patients with rheumatoid arthritis

2013 ◽  
Vol 8 (4) ◽  
pp. 161-164
Author(s):  
Neena Chitnis ◽  
Preeti Nagnur-Metha ◽  
Rohini Samant ◽  
Kaushik S. Bhojani ◽  
Vinay R. Joshi
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Onset ◽  
Lag Time

scholarly journals Formulation and evaluation of compression Coated tablets of Lornoxicam for Targeting early morning peak symptoms of Rheumatoid arthritis

2014 ◽  
Vol 12 (2) ◽  
pp. 109-117 ◽  
Author(s):  
Mohd Abdul Hadi ◽  
NG Raghavendra Rao ◽  
A Srinivasa Rao
Keyword(s):  
Rheumatoid Arthritis ◽  
Research Work ◽  
Lag Time ◽  
Early Morning ◽  
Stability Studies ◽  
In Vitro Drug Release ◽  
Dsc Studies ◽  
The Core ◽  
Ich Guidelines

In the present research work, we have designed a pulsatile formulation of lornoxicam to treat rheumatoid arthritis as per the chronotherapeutic pattern of the disease. Core tablets were prepared by incorporating different concentration of disintegrants and were compressed in between different concentration and combination of hydrophobic and hydrophilic polymers. The core and compression coated tablets were subjected to pre-formulation, physicochemical, in-vitro drug release and stability studies. FTIR and DSC studies revealed that there was not any chemical reaction between pure drug lornoxicam and polymers. The pre and post-compressional parameters of tablets were also found to be within limits. The core tablets which were incorporated with 10% of crospovidone were found to be as most fastly disintegrating. Our optimized formulation F-5 releases lornoxicam after a lag time of 5.5±0.7 hours and 99.81±0.81% upto 8 hours. Stability was also found for the optimized formulation according to ICH guidelines. Dhaka Univ. J. Pharm. Sci. 12(2): 109-117, 2013 (December) DOI: http://dx.doi.org/10.3329/dujps.v12i2.17620

Lag time between onset of symptoms and diagnosis in Venezuelan patients with rheumatoid arthritis

2010 ◽  
Vol 31 (5) ◽  
pp. 657-665 ◽  
Author(s):  
Elaudi Rodríguez-Polanco ◽  
Soham Al Snih ◽  
Yong-Fang Kuo ◽  
Alberto Millán ◽  
Martín A. Rodríguez
Keyword(s):  
Rheumatoid Arthritis ◽  
Lag Time

scholarly journals PARENT CHILD RELATIONSHIP OF SECONDARY SCHOOL GIRL CHILDREN IN THE CONTEXT OF LOCALITY AND DIFFERENT SCHOOL BACKGROUND

2017 ◽  
Vol 4 (37) ◽  
Author(s):  
J. Shakila
Keyword(s):  
Rheumatoid Arthritis ◽  
Drug Release ◽  
Research Work ◽  
Lag Time ◽  
Oral Dosage ◽  
Blood Levels ◽  
Lag Phase ◽  
Parent Child Relationship

Objective: The objective of this research work was to develop and evaluate the floating– pulsatile drug delivery system (FPDDS) of meloxicam intended for Chrono pharmacotherapy of rheumatoid arthritis. Methods: The system consisting of drug containing core, coated with hydrophilic erodible polymer, which is responsible for a lag phase for pulsatile release, top cover buoyant layer was prepared with HPMC K4M and sodium bicarbonate, provides buoyancy to increase retention of the oral dosage form in the stomach. Meloxicam is a COX-2 inhibitor used to treat joint diseases such as osteoarthritis and rheumatoid arthritis. For rheumatoid arthritis Chrono pharmacotherapy has been recommended to ensure that the highest blood levels of the drug coincide with peak pain and stiffness. Result and discussion: The prepared tablets were characterized and found to exhibit satisfactory physico-chemical characteristics. Hence, the main objective of present work is to formulate FPDDS of meloxicam in order to achieve drug release after pre-determined lag phase. Developed formulations were evaluated for in vitro drug release studies, water uptake and erosion studies, floating behaviour and in vivo radiology studies. Results showed that a certain lag time before drug release which was due to the erosion of the hydrophilic erodible polymer. The lag time clearly depends on the type and amount of hydrophilic polymer which was applied on the inner cores. Floating time and floating lag time was controlled by quantity and composition of buoyant layer. In vivo radiology studies point out the capability of the system of longer residence time of the tablets in the gastric region and releasing the drug after a programmed lag time. Conclusion: The optimized formulation of the developed system provided a lag phase while showing the gastroretension followed by pulsatile drug release that would be beneficial for chronotherapy of rheumatoid arthritis and osteoarthritis.

scholarly journals AB0201 IMPACT OF TREATMENT INITIATION DELAY ON DISEASE ACTIVITY DURING RHEUMATOID ARTHRITIS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1401.3-1401
Author(s):  
H. Bettaieb ◽  
A. Fazaa ◽  
S. Miladi ◽  
M. Sellami ◽  
O. Kmar ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Symptom Onset ◽  
Lag Time ◽  
Therapeutic Window ◽  
P Value ◽  
Sustained Remission ◽  
One Year ◽  
The Impact

Background:During rheumatoid arthritis (RA), initiating conventional synthetic Disease Modifying Anti-Rheumatic Drug (csDMARD) at the early stages of the disease is a mandatory condition to achieve DMARD-free sustained remission (1). Limited data studying the relationship between RA treatment delay and disease activity are available.Objectives:The aim of this study was to assess the impact of csDMARD initiation delay during RA on disease activity.Methods:This is a cross-sectional study including patients with RA (ACR/EULAR criteria).Delays were collected from patients’ interview and were represented respectively by D1, D2 and D3. D1 stands for the lag time separating the first RA symptom onset and rheumatologist consultation. D2 stands for the lag time separating the first RA symptom onset and RA diagnosis. D3 stands for lag time separating the first RA symptom onset and csDMARD initiation. Disease activity was evaluated by: Visual Analogue Scale for pain (VAS), number of tender joints, number of swollen joints, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and Disease Activity Score28 (DAS28).The data were analyzed with descriptive statistics, Student’s t test, chi (2) test, and Spearman correlation using the SPSS statistical package. A p value < 0.05 was considered significant.Results:The study included 100 RA patients (86 women and 14 men), with a mean age of 56.5 ± 12.4 years. The mean age at the onset of RA was 47.5 ± 12.4 years. Median D1, D2 and D3 were respectively 12 months [0-242], 15.7 months [2-252] and 18 months [2-270].Methotrextate was prescribed in 86% of cases. At RA diagnosis, the median values for the following parameters were: VAS 80 [30-100], number of tender joints 10[0-28], number of swollen joints 5 [0-17], ESR 43mm/hour [6-133], CRP 14.1 mg/l [1-120], DAS28 (ESR) 5.22 [2-7.52] and DAS28 (CRP) 4.6 [1-6.93]. After one year of follow-up, the median parameters of the disease activity were respectively: VAS 60 [0-100], number of tender joints 6[0-28], number of swollen joints 2 [0-22], ESR 32 mm/hour [2-106], CRP 7.5 mg/l [1.2-94], DAS28 (ESR) 4.1 [1.4-7.1] and DAS28 (CRP) 3.7 [1.68-6.22]. Significant positive correlation was found between delays in csDMARD initiation and DAS28 (CRP) scores over the first year (p=0.02, r=0.29).Conclusion:In this study, delays in treatment were associated with higher DAS28 (CRP) scores after one year of follow-up. Our results suggest that early identification and treatment of RA leads to improved outcomes and even improved rates of drug-free remission.References:[1]Van Nies JA, Krabben A, Schoones JW, et al. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 2014;73:861–70.Disclosure of Interests:None declared

The lag time between onset of symptoms and diagnosis of rheumatoid arthritis

1994 ◽  
Vol 37 (6) ◽  
pp. 814-820 ◽  
Author(s):  
KIN-Wei A. Chan ◽  
David T. Felson ◽  
Robert A. Yood ◽  
Alexander M. Walker
Keyword(s):  
Rheumatoid Arthritis ◽  
Lag Time

A Novel Pulsatile Release Film Coated Tablet of Zaltoprofen Loaded SNEDDS

2021 ◽  
pp. 4287-4290
Author(s):  
Rajan Kalamkar ◽  
Shailesh Wadher ◽  
Ashish Jain
Keyword(s):  
Rheumatoid Arthritis ◽  
Ethyl Cellulose ◽  
Lag Time ◽  
Drug Dissolution ◽  
In Vitro Dissolution ◽  
Dissolution Profile ◽  
Pulsatile Release ◽  
Eudragit L100 ◽  
Coated Tablet ◽  
Fast Disintegrating Tablet

The aim of the present study was to formulate pulsatile release film coated tablet of zaltoprofen for the treatment of rheumatoid arthritis. Initially solubility of zaltoprofen was enhanced by formulating self emulsifying fast disintegrating tablet of zaltoprofen. Core fast disintegrating tablet of zaltoprofen was coated with ethyl cellulose and eudragit L100 in various proportions as coating polymer. Ethanol was used as coating solvent and dibutyl phthalate as plasticizer. Film coated tablet with different coating levels were formulated and were evaluated for parameters like lag time, rupture time, in vitro dissolution etc. Amongst the nine different formulations P-4 formulation containing 3:1 ratio of ethyl cellulose and eudragit L100 with 5% coating level gives desired lag time with best drug dissolution profile. Formulated film coated tablet of zaltoprofen can be useful for chronotherapeutic treatment of rheumatoid arthritis.

Arthropathy of Down Syndrome

PEDIATRICS ◽  
1990 ◽  
Vol 86 (6) ◽  
pp. 931-936
Author(s):  
Judyann C. Olson ◽  
Joan C. Bender ◽  
Joseph E. Levinson ◽  
Alan Oestreich ◽  
Daniel J. Lovell
Keyword(s):  
Rheumatoid Arthritis ◽  
Down Syndrome ◽  
Juvenile Rheumatoid Arthritis ◽  
Lag Time ◽  
Timely Diagnosis ◽  
Time To Diagnosis ◽  
Progressive Course ◽  
Polyarticular Disease

A juvenile rheumatoid arthritis-like arthropathy has previously been documented in 12 patients with Down syndrome. An additional 9 patients are described and the literature is reviewed. It is unknown whether these patients have juvenile rheumatoid arthritis or a unique arthropathy in light of the genetic and immunologic abnormalities associated with Down syndrome. Most of the patients had a progressive course with polyarticular disease complicated by subluxations and a long lag time to diagnosis. The purpose of reporting these children is to increase awareness of this association and facilitate more appropriate and timely diagnosis of arthritis in Down syndrome patients.

Sign in / Sign up

Export Citation Format

Share Document